Literature DB >> 32205137

DDX3 inhibitors show antiviral activity against positive-sense single-stranded RNA viruses but not against negative-sense single-stranded RNA viruses: The coxsackie B model.

Paola Quaranta1, Giulia Lottini1, Giulia Chesi1, Flavia Contrafatto1, Roberta Russotto1, Lisa Macera1, Michele Lai1, Pietro Giorgio Spezia1, Annalaura Brai2, Maurizio Botta3, Giulia Freer4, Mauro Pistello5.   

Abstract

Picornaviridae are positive-sense single stranded RNA viruses with a similar genomic structure lacking a cap at the 5' end, but with a highly structured 5'-untranslated region (UTR) containing an internal ribosome entry site (IRES). IRES allows ribosomes to be recruited by the viral RNA and initiate translation in a cap-independent manner. Coxsackie virus type B (CV-B) belong to Picornaviridae and are widespread in human population. They usually cause subclinical infections but, occasionally, also severe diseases with various clinical manifestations. CV-B have no specific therapy. DEAD-box polypeptide 3 (DDX3) is a member of the Asp-Glu-Ala-Asp (DEAD)-box family with an ATP-dependent RNA unwinding helicase activity. Recently, several positive-sense single strand RNA viruses have been shown to need DDX3 for their translation. Here, we show that several DDX3 inhibitors reduced CV-B replication and production of viral protein, particularly when added within 12 h of infection. Based on in vitro and in silico data, we hypothesized that DDX3 inhibitors hamper interaction between DDX3 and viral IRES in a stereodynamic fashion. Accordingly, the DDX3 inhibitors tested have no activity against the Vesicular Stomatitis virus and Measles virus, which are negative-sense single stranded RNA viruses and use cap-dependent translation. This study suggests that DDX3 is required by RNA viruses lacking a cap and show that this enzyme is a valuable target to design antiviral molecules against CV-B. Thus, DDX3 is dispensable for cap-dependent translation, but required for translation of transcripts containing secondary structure in their UTRs.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Antivirals; Coxsackie virus; DDX3 inhibitors; DEAD-Box protein; Enterovirus; RNA genome; Ribavirin

Year:  2020        PMID: 32205137     DOI: 10.1016/j.antiviral.2020.104750

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  3 in total

1.  Molecular Docking and Molecular Dynamics Simulations Discover Curcumin Analogue as a Plausible Dual Inhibitor for SARS-CoV-2.

Authors:  Shailima Rampogu; Gihwan Lee; Jun Sung Park; Keun Woo Lee; Myeong Ok Kim
Journal:  Int J Mol Sci       Date:  2022-02-04       Impact factor: 5.923

2.  RK-33, a small molecule inhibitor of host RNA helicase DDX3, suppresses multiple variants of SARS-CoV-2.

Authors:  Farhad Vesuna; Ivan Akhrymuk; Amy Smith; Paul T Winnard; Shih-Chao Lin; Lauren Panny; Robert Scharpf; Kylene Kehn-Hall; Venu Raman
Journal:  Front Microbiol       Date:  2022-08-25       Impact factor: 6.064

Review 3.  Human Neural Stem Cell Systems to Explore Pathogen-Related Neurodevelopmental and Neurodegenerative Disorders.

Authors:  Matteo Baggiani; Maria Teresa Dell'Anno; Mauro Pistello; Luciano Conti; Marco Onorati
Journal:  Cells       Date:  2020-08-12       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.